Protalix BioTherapeutics (PLX) Total Non-Current Liabilities (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Total Non-Current Liabilities of $7.7 million for Q1 2026, up 76.96% year-over-year from $4.4 million in Q1 2025, and up 1.59% quarter-over-quarter from $7.6 million in Q4 2025.
Protalix BioTherapeutics (PLX) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $7.7 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 76.96% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (up 76.96% YoY), while the FY2025 annual figure was $7.6 million, up 65.71% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $7.7 million, up from $7.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $40.5 million in Q1 2022, with the low at $4.4 million in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $7.4 million (2025), against an average of $15.9 million.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities soared 445.93% in 2022, then slumped 84.69% in 2024.
- Protalix BioTherapeutics' Total Non-Current Liabilities stood at $34.0 million in 2022, then sank by 84.31% to $5.3 million in 2023, then slipped by 14.06% to $4.6 million in 2024, then jumped by 65.71% to $7.6 million in 2025, then grew by 1.59% to $7.7 million in 2026.
- Business Quant data shows PLX's Total Non-Current Liabilities at $7.7 million in Q1 2026, $7.6 million in Q4 2025, and $7.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 9.32 Bn |
| 10 | Protalix BioTherapeutics | 194.29 Mn | 153.63 Mn | 12.13 Mn | 7.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.54 Mn |
| Mar 31, 2026 | 7.72 Mn |
| Dec 31, 2025 | 7.60 Mn |
| Sep 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | 4.49 Mn |
| Mar 31, 2025 | 4.36 Mn |
| Dec 31, 2024 | 4.59 Mn |
| Sep 30, 2024 | 4.91 Mn |
| Jun 30, 2024 | 4.99 Mn |
| Mar 31, 2024 | 5.21 Mn |
| Dec 31, 2023 | 5.34 Mn |
| Sep 30, 2023 | 5.96 Mn |
| Jun 30, 2023 | 26.31 Mn |
| Mar 31, 2023 | 34.04 Mn |
| Dec 31, 2022 | 34.00 Mn |
| Sep 30, 2022 | 33.92 Mn |
| Jun 30, 2022 | 39.57 Mn |
| Mar 31, 2022 | 40.55 Mn |
| Dec 31, 2021 | 46.53 Mn |
| Sep 30, 2021 | 40.51 Mn |